Reyoung Pharmaceutical Co., Ltd.
-
Founded in:
1998-03-20 -
Country:
China -
Address:
No. 1, Ruiyang Road, Yiyuan County, Shandong Province -
Tax NO.:
913703001686121827 -
Registered Funds:
366.74 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Aminophylline |
Description of pharmacological actions extracted from the above information
More
Description of pharmacological actions extracted from the above information |
317-34-0 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Diclofenac sodium |
|
15307-79-6 | 55 | |
| Lidocaine |
|
137-58-6 | 43 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Tranexamic Acid |
By competitively inhibiting the adsorption of plasminogen on the fibrin network, the activation of plasminogen is reduced, thereby inhibiting the degradation of fibrin and preventing the dissolution of blood clots and bleeding.
More
By competitively inhibiting the adsorption of plasminogen on the fibrin network, the activation of plasminogen is reduced, thereby inhibiting the degradation of fibrin and preventing the dissolution of blood clots and bleeding. |
1197-18-8 | 31 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ozagrel sodium |
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.
More
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats. |
189224-26-8 | 10 |